CA3060331A1 - Coversin for the treatment of cicatrising eye inflammatory disorders - Google Patents

Coversin for the treatment of cicatrising eye inflammatory disorders Download PDF

Info

Publication number
CA3060331A1
CA3060331A1 CA3060331A CA3060331A CA3060331A1 CA 3060331 A1 CA3060331 A1 CA 3060331A1 CA 3060331 A CA3060331 A CA 3060331A CA 3060331 A CA3060331 A CA 3060331A CA 3060331 A1 CA3060331 A1 CA 3060331A1
Authority
CA
Canada
Prior art keywords
seq
coversin
protein
complement
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3060331A
Other languages
English (en)
French (fr)
Inventor
Wynne H Weston-Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1706398.3A external-priority patent/GB201706398D0/en
Priority claimed from GBGB1706406.4A external-priority patent/GB201706406D0/en
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Publication of CA3060331A1 publication Critical patent/CA3060331A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3060331A 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders Pending CA3060331A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1706398.3 2017-04-21
GBGB1706398.3A GB201706398D0 (en) 2017-04-21 2017-04-21 Method of treatment
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706406.4 2017-04-21
PCT/EP2018/060239 WO2018193120A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders

Publications (1)

Publication Number Publication Date
CA3060331A1 true CA3060331A1 (en) 2018-10-25

Family

ID=62028030

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3060331A Pending CA3060331A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders

Country Status (8)

Country Link
US (1) US20210113658A1 (enExample)
EP (1) EP3612206A1 (enExample)
JP (2) JP7153669B2 (enExample)
KR (1) KR20190138650A (enExample)
CN (1) CN110831617A (enExample)
AU (1) AU2018253960A1 (enExample)
CA (1) CA3060331A1 (enExample)
WO (1) WO2018193120A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3612208B1 (en) 2017-04-21 2023-04-05 Volution Immuno Pharmaceuticals SA Coversin for the treatment of autoimmune blistering diseases
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
AU2019468121A1 (en) 2019-09-27 2022-05-12 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
US20250313696A1 (en) 2022-05-18 2025-10-09 Asahi Kasei Kabushiki Kaisha Method for producing resin composition
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
EP2061501B1 (en) * 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Method of treating respiratory disorders
BRPI0809105A2 (pt) * 2007-03-22 2019-09-10 Novartis Ag antígenos c5 e uso destes
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
US9290736B2 (en) * 2009-11-04 2016-03-22 Case Western Reserve University Compositions and methods of treating T cell mediated disorder
EP3524258B1 (en) * 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
WO2015134673A1 (en) * 2014-03-04 2015-09-11 The Trustees Of Columbia University In The City Of New York Method for treating ocular inflammation
GB201410031D0 (en) * 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
EP3988110A1 (en) * 2015-01-28 2022-04-27 RA Pharmaceuticals, Inc. Modulators of complement activity
EP3612208B1 (en) * 2017-04-21 2023-04-05 Volution Immuno Pharmaceuticals SA Coversin for the treatment of autoimmune blistering diseases
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment

Also Published As

Publication number Publication date
WO2018193120A1 (en) 2018-10-25
JP7153669B2 (ja) 2022-10-14
JP2022188170A (ja) 2022-12-20
US20210113658A1 (en) 2021-04-22
JP2020517643A (ja) 2020-06-18
EP3612206A1 (en) 2020-02-26
AU2018253960A1 (en) 2019-10-31
KR20190138650A (ko) 2019-12-13
CN110831617A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
US20210113658A1 (en) Coversin for the treatment of cicatrising eye inflammatory disorders
US20240009270A1 (en) Coversin for the treatment of autoimmune blistering diseases
JP7603612B2 (ja) 治療法
JP2023550661A (ja) ドライアイ治療用薬の調製におけるｐ５５ｐｉｋ阻害剤の応用
JP6087429B2 (ja) 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途
EP4003396B1 (en) Tsg6 polypeptide fragment for dry eye disease
TWI889483B (zh) 具有改善乾眼症活性的新型胜肽及包括其之藥物組合物
Leonardi et al. Mechanisms of corneal allergic reaction: new options for treatment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230419

EEER Examination request

Effective date: 20230419

EEER Examination request

Effective date: 20230419